IS8318A - N3-staðgengnir imidasópýridín c-kit tálmar - Google Patents

N3-staðgengnir imidasópýridín c-kit tálmar

Info

Publication number
IS8318A
IS8318A IS8318A IS8318A IS8318A IS 8318 A IS8318 A IS 8318A IS 8318 A IS8318 A IS 8318A IS 8318 A IS8318 A IS 8318A IS 8318 A IS8318 A IS 8318A
Authority
IS
Iceland
Prior art keywords
substituted imidazopyridine
kit inhibits
inhibits
kit
imidazopyridine
Prior art date
Application number
IS8318A
Other languages
English (en)
Inventor
L. Castelhano Arlindo
Phillip Crew Andrew
Dong Han-Qing
Laufer Radoslaw
Li An-Hu
Qui Li
Sambrook Smith Colin
Zhang Tao
Original Assignee
Osi Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharmaceuticals, Inc. filed Critical Osi Pharmaceuticals, Inc.
Publication of IS8318A publication Critical patent/IS8318A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS8318A 2003-08-21 2006-02-21 N3-staðgengnir imidasópýridín c-kit tálmar IS8318A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49677603P 2003-08-21 2003-08-21
PCT/US2004/026483 WO2005021544A2 (en) 2003-08-21 2004-08-16 N3-substituted imidazopyridine-derivatives as c-kit inhibitors

Publications (1)

Publication Number Publication Date
IS8318A true IS8318A (is) 2006-02-21

Family

ID=34272515

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8318A IS8318A (is) 2003-08-21 2006-02-21 N3-staðgengnir imidasópýridín c-kit tálmar

Country Status (20)

Country Link
EP (1) EP1658289B1 (is)
JP (1) JP2007502822A (is)
KR (1) KR20060119871A (is)
CN (1) CN1839132A (is)
AP (1) AP2006003552A0 (is)
AR (1) AR045388A1 (is)
AT (1) ATE425977T1 (is)
AU (1) AU2004268950A1 (is)
BR (1) BRPI0413740A (is)
CA (1) CA2536174A1 (is)
DE (1) DE602004020073D1 (is)
IL (1) IL173615A0 (is)
IS (1) IS8318A (is)
MX (1) MXPA06002019A (is)
MY (1) MY138737A (is)
NO (1) NO20060670L (is)
RU (1) RU2006108799A (is)
SG (1) SG131944A1 (is)
TW (1) TW200519111A (is)
WO (1) WO2005021544A2 (is)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625827D0 (en) * 2006-12-22 2007-02-07 Astex Therapeutics Ltd New compounds
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2009006704A (es) 2006-12-22 2009-06-30 Astex Therapeutics Ltd Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
CN105418450A (zh) 2008-05-05 2016-03-23 赛诺菲-安万特 酰基氨基取代的稠合环戊烷羧酸衍生物及它们作为药物的用途
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
BRPI0917540A2 (pt) * 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
WO2010045276A2 (en) * 2008-10-16 2010-04-22 Cara Therapeutics, Inc. Azabenzimidazolones
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
MX2012007367A (es) * 2009-12-30 2013-04-03 Arqule Inc Compuestos substituidos de imidazopiridinilo-aminopiridina.
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
KR101974673B1 (ko) * 2011-06-24 2019-05-02 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
KR102212923B1 (ko) 2012-12-21 2021-02-04 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
DK3122748T3 (en) * 2014-03-24 2018-11-05 Arqule Inc METHOD OF PREPARING 3- (3- (4- (1-AMINOCYCLOBUTYL) PHENYL) -5-PHENYL-3H-IMIDAZO [4,5-B] PYRIDIN-2-YL) PYRIDIN-2-AMINE
EP3594206A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3594205A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022021920A2 (pt) 2020-04-29 2023-01-17 Plexxikon Inc Síntese de compostos heterocíclicos
WO2024117179A1 (en) * 2022-11-30 2024-06-06 Alivexis, Inc. Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW251284B (is) * 1992-11-02 1995-07-11 Pfizer
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
US20020072530A1 (en) 2000-02-01 2002-06-13 Bing-Yan Zhu Indole and benzimidazole inhibitors of factor Xa
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
AP2006003552A0 (en) 2006-04-30
AR045388A1 (es) 2005-10-26
IL173615A0 (en) 2006-07-05
AU2004268950A1 (en) 2005-03-10
CA2536174A1 (en) 2005-03-10
TW200519111A (en) 2005-06-16
ATE425977T1 (de) 2009-04-15
MXPA06002019A (es) 2006-05-31
NO20060670L (no) 2006-05-12
KR20060119871A (ko) 2006-11-24
JP2007502822A (ja) 2007-02-15
WO2005021544A3 (en) 2005-06-16
DE602004020073D1 (de) 2009-04-30
EP1658289A2 (en) 2006-05-24
MY138737A (en) 2009-07-31
RU2006108799A (ru) 2006-07-27
CN1839132A (zh) 2006-09-27
BRPI0413740A (pt) 2006-10-24
WO2005021544A2 (en) 2005-03-10
SG131944A1 (en) 2007-05-28
EP1658289B1 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
IS8318A (is) N3-staðgengnir imidasópýridín c-kit tálmar
ATE481402T1 (de) Pyrazolopyridin-derivate
CY2014018I1 (el) Kαρβαμιδο - υποκατεστημενες πυραζολοπυριδινες
ATE415400T1 (de) Pyrazolopyridinderivate
IS8319A (is) N-staðgengnir bensimidasólýl c-kit tálmar
DE602004006781D1 (de) Schlingenware
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
ATE352550T1 (de) Chinazolinderivate
DK1682493T3 (da) Amidoacetonitrilderivater
DK1606277T3 (da) Imidazol-4-yl-ethynyl-pyridinderivater
ATE421506T1 (de) Neue benzimidazolderivate
DK1597007T3 (da) Borepatron
ATE412651T1 (de) Pyrrolopyridinderivate
DE602004001733D1 (de) Horizontal-Bearbeitungszentrum
ATE354365T1 (de) N-thiazol-2-yl-benzamid-derivate
DE602004001599D1 (de) Mehrlagige Bürste
DE602004023159D1 (de) Bearbeitungszentrum
DK1706373T3 (da) Amidoacetonitrilderivater
IS8045A (is) Púrín-6-ón-afleiður
ATE489386T1 (de) Naphthyridin-derivate
ATA2742003A (de) Objekttisch
NO20030754D0 (no) Nöd-slepeline
SE0400572D0 (sv) Tandborste
FI20031313A0 (fi) Ultima